



CENTRO TRAPIANTO FEGATO
Turin Liver Transplant Center
Torino

FIRST INTERNATIONAL WORKSHOP ON LIVER MACHINE PERFUSION

Centro Congressi
Unione Industriale Torino
June 10-11, 2022




RATIONALE

The introduction of machine perfusion as a preservation modality alternative to static cold storage has prompted a veritable revolution in liver transplantation, leading to an evolution in clinical practice, widening therapeutic horizons and paving the way for new treatment possibilities, for both patients and liver grafts. The possibilities of ex-situ organ treatment or “reconditioning” are manifold and include the administration of antibiotics, immunoglobulins or other drugs to prevent the transmission of donor-derived infections.

The current scenario is characterized by a plurality of different approaches that differ with regards to timing, technical modalities, and logistical implications. While robust data are emerging about the respective benefits and drawbacks of different machine perfusion modalities, clinical implications, potential developments and new applications of this technology are heatedly discussed.

After these last two years during which COVID-19 pandemic has greatly limited the opportunity to organize in-person meetings, this event set out as an opportunity to gather top experts in the field to discuss the state of the art in liver machine perfusion, real-life clinical indications, implications for immunosuppressive therapy, and future developments of the technology.



Day 1 | Friday, 10th June 2022

Opening Remarks

Mauro Salizzoni, Renato Romagnoli

Session 1 Clinical applications of liver machine perfusion

Chairpersons: Luciano De Carlis, Cristiano Quintini

- 13:00-13:15** Impact of machine perfusion introduction on liver transplant activity in Italy: present and future
Silvia Trapani, Massimo Cardillo
- 13:15-13:30** Implementation and results of Innsbruck normothermic machine perfusion program
Felix Krendl, Stefan Schneeberger
- 13:30-13:45** Dual hypothermic oxygenated machine perfusion for livers from extended-criteria brain-dead donors improves graft survival: an inverse probability of treatment weighting analysis
Damiano Patrono, Renato Romagnoli
- 13:45-14:00** Hypothermic oxygenated machine perfusion for livers from extended-criteria brain-dead donors improves graft survival: a randomized controlled trial
Matteo Ravaioli, Matteo Cescon
- 14:00-14:15** Hypothermic oxygenated machine perfusion for livers from extended-criteria brain-dead donors: results, limits and future directions
Zoltan Czigan, Georg Lurje

Session 2 State of the art in liver machine perfusion

Chairpersons: Patrizia Burra, Renato Romagnoli

- 14:30-14:45** Outcomes and risk factors of graft loss in liver transplantation from cDCD donors treated with postmortem normothermic regional perfusion in Spain
Constantino Fondevila

- 14:45-15:00** Normothermic machine perfusion: state of the art and future perspectives
Peter J. Friend

- 15:00-15:15** Ischemia-free liver transplantation
Zhiyong Guo

- 15:15-15:30** Machine perfusion in the US
Malcolm P. MacConmara

- 15:30-15:45** Zurich machine perfusion experience
Philipp Dutkowski

- 15:45-16:00** Groningen machine perfusion experience
Robert J. Porte

- 16:00-16:15** Liver viability assessment during normothermic regional perfusion and normothermic machine perfusion: results and comparison with static cold storage
Christopher JE Watson

- 16:15-16:45** Which endpoints for liver machine perfusion trials?
Vatche G Agopian
Discussant: Alfonso Avolio

- 16:45-17:15** *Coffee break*

Session 3 Normothermic regional perfusion and liver transplantation using donors after circulatory death

Chairpersons: Massimo Cardillo, Xavier Michel Mueller

- 17:15-17:30** Normothermic regional perfusion: technical aspects and organ evaluation
Alberto Zanella, Marinella Zanierato

- 17:30-17:45** Normothermic regional perfusion and machine perfusion in liver transplantation with donors after circulatory determination of death
Andrea Schlegel, Paolo Muiesan †

- 17:45-18:00** Outcome of Maastricht category 3 grafts with long functional ischemia time
Luciano De Carlis, Riccardo De Carlis

18:00-18:15 Outcome of Maastricht category 2 grafts with long functional warm ischemia time
Davide Ghinolfi, Paolo De Simone

18:15-18:30 Impact of hypothermic oxygenated machine perfusion on biliary strictures following liver transplantation with donors after circulatory determination of death
Robert J. Porte, Rianne Van Rijn

Day 2 | Saturday, 11th June 2022

Session 4 Viability assessment and other controversial issues in machine perfusion

Chairpersons: **Salvatore Gruttadauria, Paulo Martins**

9:00-9:15 Viability assessment during NMP
Hynek Mergental, Darius Mirza

9:15-9:30 Viability assessment during hypothermic oxygenated machine perfusion
Janina Eden, Philipp Dutkowski

9:30-9:45 Perfusate analysis during normothermic machine perfusion: beyond the routine
Andras Meszaros, Stefan Schneeberger

9:45-10:00 Beyond early allograft dysfunction: how to assess liver injury and function after ex-situ perfusion?
Daniele Dondossola, Paolo Muesan †

10:00-10:15 Hypothermic oxygenated machine perfusion for fatty liver grafts
Richard Sousa da Sousa, Philipp Dutkowski

10:15-10:30 Dual hypothermic oxygenated machine perfusion as a tool to prolong preservation time
Robert J. Porte, Isabel M.A. Brüggewirth

10:30-11:00 *Coffee break*

Session 5 Perspectives in machine perfusion

Chairpersons: **Umberto Cillo, Federico Genzano Besso**

11:00-11:15 Defatting during normothermic machine perfusion
Carlo Ceresa

11:15-11:30 Donor-derived infections and NMP: threat or opportunity?
David Nasralla

11:30-11:45 In-situ isolated normothermic liver chemoperfusion
Tamsyn Clark

11:45-12:00 Upfront versus end-ischemic hypothermic oxygenated machine perfusion: time for a paradigm shift?
Andrea Schlegel

12:00-12:15 Extracellular vesicles from human liver stem cells to mitigate ischemia-reperfusion injury during normothermic machine perfusion
Nicola De Stefano, Giovanni Camussi

12:15-12:30 Liver preservation: from the pig to humans
Nicholas Gilbo, Diethard Monballiu

12:30-12:45 Biliary organoids and cholangiocyte repair during normothermic machine perfusion
Fotios Sampaziotis, Christopher JE Watson

12:45-13:00 Hepatocellular carcinoma recurrence, rejection and immunosuppressive therapy after dual hypothermic oxygenated machine perfusion
Federica Rigo, Damiano Patrono

SCIENTIFIC SECRETARIAT

Renato Romagnoli

*Professor of Surgery
Head, Liver Transplant Center
University of Turin
Italy*

FACULTY

Vatche G Agopian, *Los Angeles*

Alfonso W. Avolio, *Roma*

Isabel M.A. Brüggewirth, *Groningen*

Patrizia Burra, *Padova*

Giovanni Camussi, *Torino*

Massimo Cardillo, *Roma*

Carlo Ceresa, *Oxford*

Matteo Cescon, *Bologna*

Umberto Cillo, *Padova*

Tamsyn Clark, *Oxford*

Zoltan Czigany, *Aachen*

Luciano De Carlis, *Milano*

Riccardo De Carlis, *Milano*

Paolo De Simone, *Pisa*

Nicola De Stefano, *Torino*

Daniele Dondossola, *Milano*

Philipp Dufkowsky, *Zurich*

Janina Eden, *Zurich*

Constantino Fondevila, *Madrid*

Peter J. Friend, *Oxford*

Federico Genzano Besso, *Torino*

Davide Chinolfi, *Pisa*

Nicholas Gilbo, *Leuven*

Salvatore Gruttadauria, *Palermo*

Zhiyong Guo, *Guangzhou*

Felix Krendl, *Innsbruck*

Georg Lurje, *Berlino*

Malcolm P. MacConmara, *Dallas*

Paulo Martins, *Worcester-USA*

Hynek Mergental, *Birmingham*

Andras Meszaros, *Innsbruck*

Darius Mirza, *Birmingham*

Diethard Monbaliu, *Leuven*

Paolo Muiesan †, *Milano*

Xavier Muller, *Lyon*

David Nasralla, *London*

Damiano Patrono, *Torino*

Robert J. Porte, *Groningen*

Cristiano Quintini, *Cleveland*

Matteo Ravaioli, *Bologna*

Federica Rigo, *Torino*

Renato Romagnoli, *Torino*

Mauro Salizzoni, *Torino*

Fotios Sampaziotis, *Cambridge*

Andrea Schlegel, *Milano*

Stefan Schneeberger, *Innsbruck*

Richard Xavier Sousa Da Silva, *Zurich*

Silvia Trapani, *Roma*

Rianne Van Rijn, *Groningen*

Christopher JE Watson, *Cambridge*

Alberto Zanella, *Milano*

Marinella Zanierato, *Torino*

GENERAL INFORMATION

CONGRESS VENUE

Unione Industriale Torino

Via Vincenzo Vela, 17

10128 Torino (Italy)

CME PROVIDER

The event CME RES **38-346788** has been granted **no. 8 CME credits**.

Accredited Professions: Surgeons (Disciplines: Pathological anatomy, Anesthesia and Reanimation, Cardiac surgery, Cardiology, General surgery, Pediatric surgery, Vascular surgery, Gastroenterology, Medical genetics, Laboratory medicine, Infectious diseases, General medicine, Internal medicine, Nephrology, Oncology, Clinical pathology, Pulmonology, Radiodiagnosics, Food science and dietetics) Biologist, Dietitian, Hospital Pharmacist, Nurse, Pediatric Nurse, Psychologist, Perfusionist Technician, Medical Radiology Health Technician

REGISTRATION

The congress is free to attend but the access is limited to 150 people. You can register at <https://webplatform.planning.it/Trapianti2022/register>

#STAYSAFE

To ensure the safety of speakers, participants, sponsors, technical staff and support staff, PLANNING applies an **anti-contagion protocol** in the organization of each residential

event in compliance with the Decrees of the Presidency of the Council of Ministers in force at the date of the event, available on the website www.planning.it.

The CME Provider Planning Congressi srl has activated a platform for filling out the CME Online Questionnaire. For the purposes of the acquisition of educational credits, the effective presence of 90% of the total duration of the event and at least 75% of the correct answers to the learning evaluation questionnaire is ESSENTIAL.

Filling out the questionnaire will entitle you to credits ONLY if associated with the verification of actual attendance at the event. There will be no exceptions to these obligations.

TRAINING OBJECTIVE

Implementation of culture and safety in the field of transplant donation.

CONGRESS ORGANIZER & SECRETARIAT



PLANNING Congressi Srl

Via Guelfa, 9

40138 Bologna (Italy)

Project Leader: Alessia Arena

M. +39 346 501 5090

a.arena@planning.it

www.planning.it

With the non-conditioning
sponsorship of



GRIFOLS



KEDRION
BIOFARMA



NOVARTIS



SANDOZ A Novartis Division